MedTrace Logo

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

NCT03053167 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-02-14

No results posted yet for this study

Summary

Irinotecan and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles. The purpose of this study is to evaluate efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer patients.

Conditions

Interventions

DRUG

Irinotecan

Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks

DRUG

Raltitrexed

Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks

Sponsors & Collaborators

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • Shengjing Hospital

    collaborator OTHER

  • General Hospital of Shenyang Military Region

    collaborator OTHER

  • China Medical University, China

    lead OTHER

Principal Investigators

  • YunPeng Liu, PhD · First Hospital of China Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03053167 on ClinicalTrials.gov